More recently, 30 HBeAg-negative patients with chronic HBV/HDV co-infection were randomized in 2 arms and treated for 48 weeks with either 10 mg bulevirtide/day plus peg-IFN-α-2a QW or 5 mg of bulevirtide given twice daily + TDF 245 mg/day [123]. The gene discussed is IFNA2; the disease is coinfection.